Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib

In chronic lymphocytic leukemia (CLL), a deeper understanding of the disease biology led over the last decade to the development and clinical use of different targeted drugs, including Bruton tyrosine kinase (BTK) inhibitors. The first BTK inhibitor approved for clinical use is ibrutinib, which show...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Candida, Gibbons, Jamie Lynn, Ferrajoli, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721287/
https://www.ncbi.nlm.nih.gov/pubmed/35002256
http://dx.doi.org/10.2147/OTT.S303060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721287/
https://www.ncbi.nlm.nih.gov/pubmed/35002256
http://dx.doi.org/10.2147/OTT.S303060

Ejemplares similares